FDA Approves First Generic Versions of Cymbalta

The FDA has approved the first generic versions of Cymbalta (duloxetine delayed-release; Eli Lilly) capsules.

Cymbalta is indicated for generalized anxiety disorder, fibromyalgia, major depressive disorder, chronic musculoskeletal pain, and diabetic peripheral neuropathic pain. 

RELATED: Psychiatric Disorders Resource Center

The exact mechanisms of the antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, but these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.

The FDA has granted marketing approval to the following companies: Aurobindo Pharma, Dr. Reddy's Laboratories, Lupin, Sun Pharma Global FZE, Teva Pharmaceuticals, and Torrent Pharmaceuticals.

Information about the available strengths and packaging of generic duloxetine can be obtained from the manufacturers.

For more information call (888) 463-6332 or visit FDA.gov

Loading links....